Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma
Authors
Keywords
-
Journal
LEUKEMIA
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-07-24
DOI
10.1038/s41375-019-0517-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Combination therapy with carfilzomib, lenalidomide and dexamethasone (KRd) results in an unprecedented purity of the stem cell graft in newly diagnosed patients with myeloma
- (2018) Nishant Tageja et al. BONE MARROW TRANSPLANTATION
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
- (2018) David S. Siegel et al. JOURNAL OF CLINICAL ONCOLOGY
- Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study
- (2018) Philippe Moreau et al. LANCET ONCOLOGY
- Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity
- (2018) Nikoletta Lendvai et al. LEUKEMIA & LYMPHOMA
- Carfilzomib-Associated Cardiovascular Adverse Events
- (2018) Adam J. Waxman et al. JAMA Oncology
- Global Burden of Multiple Myeloma
- (2018) Andrew J. Cowan et al. JAMA Oncology
- Patient-Reported Outcomes (PROs) From the Phase 3 A.R.R.O.W. Study Comparing Once-Weekly versus Twice-Weekly Carfilzomib Dosing in Relapsed and Refractory Multiple Myeloma (RRMM)
- (2018) Philippe Moreau et al. Clinical Lymphoma Myeloma & Leukemia
- Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone
- (2018) Dickran Kazandjian et al. JAMA Oncology
- An overview of the role of carfilzomib in the treatment of multiple myeloma
- (2017) Dimitrios C. Ziogas et al. EXPERT OPINION ON PHARMACOTHERAPY
- Cardiovascular events during carfilzomib therapy for relapsed myeloma: practical management aspects from two case studies
- (2017) Andrzej J. Jakubowiak et al. Hematology
- Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes
- (2017) O. Landgren et al. JOURNAL OF INTERNAL MEDICINE
- Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial
- (2017) Meletios A Dimopoulos et al. LANCET ONCOLOGY
- Management of Carfilzomib-Associated Cardiac Adverse Events
- (2016) Joseph Mikhael Clinical Lymphoma Myeloma & Leukemia
- Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma
- (2016) A. Keith Stewart et al. JOURNAL OF CLINICAL ONCOLOGY
- Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
- (2016) Meletios A Dimopoulos et al. LANCET ONCOLOGY
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
- (2016) Shaji Kumar et al. LANCET ONCOLOGY
- Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD®immunomodulatory drug pomalidomide
- (2015) Deepika S. Das et al. BRITISH JOURNAL OF HAEMATOLOGY
- Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma
- (2015) Joseph R. Mikhael et al. BRITISH JOURNAL OF HAEMATOLOGY
- Minimal residual disease in multiple myeloma: bringing the bench to the bedside
- (2015) Sham Mailankody et al. Nature Reviews Clinical Oncology
- Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
- (2015) A. Keith Stewart et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma
- (2015) Neha Korde et al. JAMA Oncology
- Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study
- (2014) S. Bringhen et al. BLOOD
- Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma
- (2014) P. Sonneveld et al. BLOOD
- Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma
- (2014) D. Dytfeld et al. HAEMATOLOGICA
- Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies
- (2013) D. Siegel et al. HAEMATOLOGICA
- Macrolide antibiotics block autophagy flux and sensitize to bortezomib via endoplasmic reticulum stress-mediated CHOP induction in myeloma cells
- (2013) SHOTA MORIYA et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
- (2012) A. J. Jakubowiak et al. BLOOD
- The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects
- (2012) M A Hurchla et al. LEUKEMIA
- In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells
- (2011) Dharminder Chauhan et al. CLINICAL CANCER RESEARCH
- Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events
- (2011) S. Arastu-Kapur et al. CLINICAL CANCER RESEARCH
- Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues
- (2010) Michel Delforge et al. LANCET ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search